Marc Casellas (SOM Innovation Biotech S.L. (SOM Biotech))

Casellas, Marc (SOM Biotech 202106– CFO before Ysios Capital Partners + Danone Group + PwC Consulting)

	Organisation	SOM Innovation Biotech S.L. (SOM Biotech)
	Former/major organisation	Ysios Capital Partners SGECR S.A.
	Group	Ysios Capital (Group)
	Product	biopharmaceutical
	Product 2	finance

SOM Biotech S.L.. (6/23/21). "Press Release: SOM Biotech Appoints Marc Casellas as Chief Financial Officer". Barcelona.

SOM Biotech, a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, announces the appointment of Marc Casellas as Chief Financial Officer.

Mr Casellas has an extensive finance experience across the healthcare and venture capital sectors, specially in providing financing to life science companies at different stages of growth. Prior to joining SOM Biotech, Marc Casellas most recently served as Chief Financial Officer of Ysios Capital after holding finance positions at Danone Group and PwC Consulting.

Raúl Insa, CEO of SOM Biotech highlights: “Marc Casellas has a deep expertise in managing finance in biotech and in venture capital. He will provide all aspects of financial and administration leadership in support of driving value creation. It is a great time to incorporate Marc Casellas to our team, to further align financial strategy with our corporate goals. We look forward to strengthening our management team as we enter our next phase of growth.”

About SOM Biotech:

SOM Biotech (www.sombiotech.com) – established in 2009 – is a biopharmaceutical company based in Barcelona, Spain. SOM has an extensive portfolio of products that includes drugs for orphan diseases including TTR Amyloidosis, Huntington's disease, Phenylketonuria, Niemann-Pick C, Glioblastoma and Parkinson’s disease. The company engages in accelerated discovery of therapies through a proprietary artificial intelligence-based computational technology (SOMAI PRO) and develops strategic partnerships with major research centers and pharmaceutical companies.

Katja Görnemann
Investor Relations & Corporate Communication
Tel: +34 696135428